文献速递心力衰竭与心肌病血脂与心血管预防

重新定义肥厚型心肌病的遗传架构:中等效应变异的作用

Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants.
PubMed 文献 · Circulation · 2025-08-29

建议HCM基因检测时评估IEV。

要点

  • IEV见于6.1%的HCM病例,孤立IEV占4.8%,其中65.3%位于非肌节基因。
  • IEV携带者比基因阴性患者诊断年龄更小、左室最大壁厚更大。
  • IEV与单基因变异共存时表型更侵袭,70岁时无主要不良心脏事件生存率显著更低。

核心结论

  • IEV存在于6.1%的HCM病例中,占HCM遗传负担的4.8%。
  • IEV影响疾病严重程度和结局,尤其与单基因致病变异共存时。
  • 建议HCM基因检测时考虑评估IEV。

研究设计与样本

  • 基于祖源的富集分析,纳入14个验证HCM基因(9个核心肌节基因和5个非肌节基因)。
  • 计算人群归因分数以评估IEV对HCM的贡献。

主要发现

  • 在731例(占队列6.1%)个体中鉴定出8个基因的14个IEV,其中570例(4.8%)为孤立IEV:198例(34.7%)在肌节基因,372例(65.3%)在非肌节基因。
  • IEV对HCM遗传学的人群归因分数估计为4.9%(95%CI,3.2-6.7)。
  • 与基因阴性患者相比,IEV携带者诊断中位年龄更小(59岁[95%CI,46-69] vs 61岁[95%CI,49-70];P=0.0073),左室最大壁厚均值更高(18.1±3.7 vs 19.0±4.3;P=0.0043)。
  • IEV修饰单基因变异个体的疾病表达,导致比仅单基因组更侵袭的表型,HCM发病年龄更小、左室最大壁厚更高(均P<0.0001),70岁时无主要不良心脏事件生存率显著更低(93.3% vs 69.3%;P<0.0001)。

临床怎么用

  • HCM基因检测时应评估IEV,以更全面解释遗传架构。
  • IEV携带者可能需要更早诊断和更密切的表型监测。
  • IEV与单基因变异共存提示更高风险,可指导预后咨询。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder linked primarily to rare variants in sarcomeric genes, although recently certain nonsarcomeric genes have emerged as important contributors. Nonmendelian genetic variants with reproducible moderate-effect sizes and low penetrance, intermediate-effect variants (IEVs), can play a crucial role in modulating disease expression. Understanding the clinical impact of IEVs is crucial to unravel the complex genetic architecture of HCM. METHODS: We conducted an ancestry-based enrichment analysis of 14 validated HCM genes, including the 9 core sarcomeric and 5 nonsarcomeric genes (ALPK3, CSRP3, FHOD3, FLNC, and TRIM63). Enrichment of intermediate frequency missense variants was evaluated in 10 981 patients with HCM, 4030 internal controls of European-ancestry, and 590 000 external controls from gnomAD non-Finnish Europeans. The population-attributable fraction was calculated to assess contribution of IEVs to HCM. Age-related disease penetrance, phenotypic severity (left ventricular maximum wall thickness), and major adverse cardiac events were analyzed in 11 991 HCM cases of the whole cohort according to 5 genetic groups: genotype negative, isolated IEV, monogenic, monogenic+IEV, and double monogenic. RESULTS: Fourteen IEVs in 8 genes were identified in 731 individuals (6.1% of the cohort), of whom 570 patients (4.8%) had IEVs in isolation: 198 (34.7%) in sarcomeric genes and 372 (65.3%) in nonsarcomeric genes. The contribution of IEVs to HCM genetics according to population-attributable fraction was estimated to be 4.9% (95% CI, 3.2-6.7). A significant gradient in penetrance, phenotypic severity, and major adverse cardiac events was observed across genetic groups. Compared with genotype-negative patients, IEV carriers displayed a younger median age at diagnosis (59 years of age [95% CI, 46-69] versus 61 years [95% CI, 49-70]; P=0.0073) and a higher mean left ventricular maximum wall thickness (18.1±3.7 versus 19.0±4.3; P=0.0043). IEVs also modified disease expression in individuals with monogenic variants, causing a more aggressive phenotype than in individuals from the monogenic-only group with HCM onset at younger age and a higher left ventricular maximum wall thickness (all P<0.0001), with major adverse cardiac event-free survival being significantly lower (93.3% versus 69.3% at 70 years of age; P<0.0001). CONCLUSIONS: IEVs are present in 6.1% of HCM cases and account for 4.8% of HCM genetic burden. IEVs also influence disease severity and outcomes, particularly when combined with monogenic disease-causing variants. Evaluation of IEVs should be considered when HCM genetic testing is performed.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. García Hernandez S, de la Higuera Romero L, Fernandez A, et al. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants. Circulation. 2025. PMID: 40879562. doi:10.1161/CIRCULATIONAHA.125.074529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。